StockData
Braveheart Bio, Inc. logo

Braveheart Bio, Inc. (BRVE) company profile

BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$18.78−0.71 (-3.64%)

Close on Nov 17, 2026Market cap $1.69BP/E –Yield –

About Braveheart Bio

Pharmaceutical Preparations, SIC 2834

Braveheart Bio, Inc. is listed on Nasdaq under the ticker BRVE, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.

Company profile

Company

Legal name
Braveheart Bio, Inc.
Headquarters
San Francisco, CA
Address
One Letterman Dr., Bldg. A, Ste. A4-300 94129
Phone
(415) 707-6312
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31

Stock & identifiers

Ticker
BRVE
Exchange
Nasdaq
IPO date
Aug 6, 2026
Shares outstanding
90M, Sep 3, 2026
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
2131524
CUSIP
10567X101
ISIN
US10567X1019
FIGI
BBG01YCFNLC2
Share class FIGI
BBG01YCFNLV1
EIN
99-2981994

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Travis MurdochCEO and President, Director8,333,637
Michele A. AndersonChief Development Officer332,161
James Paul RickeyChief Financial Officer703,575
Vineeta AgarwalaDirector10,232,420
Erez ChimovitsDirector273,333
Genesis GP LLC OrbiMedDirector273,333
Capital GP IX LLC OrbiMedDirector–
Advisors Llc OrbimedDirector1,102,739
David Charles LubnerDirector55,555
Jasper BosDirector–
Christopher ViehbacherDirector759,857
Tim LohoffDirector–
David I. MalekDirector1,013,297
Jason V. ColomaDirector1,100,456

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Aug 6, 2026
Offer price
$18.00
Securities offered
21,250,000
Gross proceeds
$382.50M
Exchange
Nasdaq
First trading day
Aug 6, 2026
First-day close
$29.80+65.6%
Lock-up ends (est.)
Feb 2, 2027

“The initial public offering price per share is $18.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?